{
    "clinical_study": {
        "@rank": "16574", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Primary: To evaluate food effect on the pharmacokinetics (PK) of a single oral dose of\n           CJ-12420 in healthy male subjects.\n\n        -  Secondary\n\n             -  To explore food effect on the pharmacodynamics (PD) of single oral dose of\n                CJ-12420 in healthy male subjects(PD/PK group)\n\n             -  To evaluate the safety of single oral dose of CJ-12420 in healthy male subjects\n                under fed or fasting condition."
        }, 
        "brief_title": "Food-Effect on PK and PD of Single Oral Dose of CJ-12420 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male volunteers in the age between 20 and 45 years old(inclusive)\n\n          -  Body mass index (BMI) in the range of 19 to 28 kg/m2 and weighing at least 50 kg\n             (inclusive)\n\n          -  Medically healthy with no clinically significant vital signs (sitting position blood\n             pressure, pulse rate)\n\n               1. 90 mmHg \u2264 systolic blood pressure \u2264 140 mmHg\n\n               2. 50 mmHg \u2264 diastolic blood pressure \u2264 95 mmHg\n\n               3. 45 beats per minute \u2264 pulse rate \u2264 95 beats per minute\n\n          -  Understand the requirements of the study and voluntarily consent to participate in\n             the study\n\n        Exclusion Criteria:\n\n        Subjects will be excluded from the study if there is evidence of any of the following\n        criteria: Last three criteria will be applied ONLY to PD/PK group.\n\n          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,\n             hematologic, endocrine, oncologic, pulmonary,immunologic, psychiatric,\n             musculoskeletal or cardiovascular disease or any other condition, which, in the\n             opinion of the Investigator, would jeopardize the safety of the subject or impact the\n             validity of the study results\n\n          -  History of allergy or sensitivity to any drug, including any prior serious adverse\n             reaction to PPIs (e.g. omeprazole, rabeprazole, lansoprazole)\n\n          -  History of symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer,\n             Barrett's esophagus or Zollinger-Ellison syndrome, previous positive H. pylori\n\n        The following criteria will be applied ONLY to PD/PK group\n\n          -  H.pylori positive, as determined by the urea breath test\n\n          -  Urine cotinine test positive\n\n          -  Subject who were unable to be applicable for pH meter catheter"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830309", 
            "org_study_id": "CJ_APA_102"
        }, 
        "intervention": {
            "arm_group_label": [
                "Sequence 1", 
                "Sequence 2"
            ], 
            "description": "Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition\nPeriod1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition", 
            "intervention_name": "CJ-12420 200mg", 
            "intervention_type": "Drug", 
            "other_name": "CJ-12420"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Food-Effect", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "April 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Study to Evaluate Food-Effect on Pharmacokinetics and Pharmacodynamics of Single Oral Dose of CJ-12420 in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Kyun-Seop Bae, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Geometric mean ratio and 90% CI for log-transformed AUClast", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling during 24 or 48 hrs after administration"
            }, 
            {
                "measure": "Geometric mean ratio and 90% CI for log-transformed Cmax", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling during 24 or 48 hrs after administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "time pH > 4", 
            "safety_issue": "No", 
            "time_frame": "24 hour before and after IP administration"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}